Abstract
Human adenovirus type F-41 has been pursued as one of the potential reasons for the new acute hepatitis cases of unknown cause in young children. Tracking the spread of this virus in the population using wastewater-based epidemiology tools can help clinical investigations to determine its relation to this new hepatitis outbreak.
In this study, methods to detect human adenovirus type F (40 and 41) and specifically type F41 were designed and implemented to quantify the amount of these pathogens in wastewater samples from Stockholm, Sweden. An assay based on reverse transcriptase quantitative polymerase chain reaction using TaqMan technology and primers targeting the three main capsid genes of adenoviruses: hexon, penton and fiber, was designed. The hexon primers were specific to adenovirus F41, while fiber primers could quantify both adenoviruses, F40 and F41. Wastewater samples from Stockholm were used to validate the designed assay and, in addition, pepper mild mottle virus (PMMoV) levels were quantified to study the data normalization.
Our results can help link the occurrence of the virus variant with new cases of acute hepatitis and contribute to a better understanding of the possible causes. It can also provide valuable information that can be used in future investigations on the monitoring of human adenovirus type F in wastewater.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by SciLifeLab, Pandemic Laboratory Preparedness (VC-2021-0033), and the Knut and Alice Wallenberg Foundation (KAW 2020.0241, V-2020-0699).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
